Trial Profile

An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO With Open-Label Safety Period in Pediatric Subjects With Epilepsy

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diazepam (Primary)
Indications Epilepsy; Generalised seizures; Partial epilepsies
Focus Pharmacokinetics; Registrational
Acronyms Stellina™
Sponsors Neurelis

Most Recent Events

05 Dec 2025 Results published in the Neurelis Media Release.
05 Dec 2025 According to a Neurelis media release, the company will present 6 posters which include final analyses of data from the completed Stellina study in the American Epilepsy Society (AES) Annual Meeting December 5-9, 2025 in Atlanta.
16 May 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com